Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics, announced that it has initiated a phase 2 clinical proof of concept trial of TC-5619 in cognitive dysfunction in schizophrenia.
Link:
Targacept starts phase 2 study of TC-5619 in cognitive dysfunction in schizophrenia (PharmaBiz)
